Clinical Trials
106 trialsPSMAddition
Novartis
PSMACare
Novartis
PSMA SRT
Jonsson Comprehensive Cancer Center
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Novartis
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
Novartis
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
Endocyte
SatisfACtion
Novartis
Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
First Affiliated Hospital of Fujian Medical University
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
Memorial Sloan Kettering Cancer Center
PSMA PET Response Guided SabR in High Risk Pca
University of Texas Southwestern Medical Center
Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
Weill Medical College of Cornell University
PSMAfore
Novartis
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Jonsson Comprehensive Cancer Center
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
Jonsson Comprehensive Cancer Center
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Novartis
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
Novartis
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy
Jonsson Comprehensive Cancer Center
68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer
Mayo Clinic
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
University of Washington
NeoPSMA
Novartis
Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study
UNC Lineberger Comprehensive Cancer Center
68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer
Mayo Clinic
68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
First Affiliated Hospital of Fujian Medical University
68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients
Peking Union Medical College Hospital
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
Weill Medical College of Cornell University
An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma
Mayo Clinic
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic
BiPASS
Telix Pharmaceuticals (Innovations) Pty Limited
68Ga-PSMA PET/CT for Ra223 Assessment
Chang Gung Memorial Hospital
Re-treatment 225Ac-J591 for mCRPC
Weill Medical College of Cornell University
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
Jonsson Comprehensive Cancer Center
68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic
HEATWAVE
Jonsson Comprehensive Cancer Center
PPPIMS
Royal Marsden NHS Foundation Trust
[68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate Cancer
British Columbia Cancer Agency
PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer
Mayo Clinic
MORE-PSMA
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer
Emory University
GaPSMA
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
BASKET PSMA
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer
Mayo Clinic
Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC
University of Iowa
High Precision Imaging of Prostate Specific Membrane Antigen for Personalized Treatment in Prostate Cancer
Universitaire Ziekenhuizen KU Leuven
68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
Telix Pharmaceuticals (Innovations) Pty Limited
PET/MRI to Stage Prostate Cancer Patients
IRCCS San Raffaele
Phase I Trial of 225Ac-J591 in Patients With mCRPC
Weill Medical College of Cornell University
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
Emory University